Diabetes treatment is constantly evolving, with new therapeutic options developing to improve patient outcomes. Recent investigations have focused on GLP-1 and GIP receptor agonists, a class of drugs that mimic the actions of naturally occurring hormones involved in bloodsugar regulation. These novel agents demonstrate promising results in managing

The burgeoning landscape of treatment for glp-2 weight management and type 2 metabolic disorder is currently witnessing considerable interest surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant variations in their pharmacological profiles and clinical study results are emerging. R

Retaglutide and tirzepatide represent innovative type of medications known as dual GLP-1 and GIP agonists. These agents influence both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that perform a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones